New Generation of Promising Immunotherapeutics Approaches for Psoriasis Dilemma; IL-35 Gene as a Potentiated Candidate

Psoriasis is immune-mediated chronic inflammatory disorder related to Th1 pattern, in which, 2 to 3% of white population worldwide have been affected. It is demonstrated that excessive secretion of pro-inflammatory cytokines such as IL-17A, TNF-α, IL-6, IFN-γ, IL-2 and IL-12 are involved in the immunopathogenesis and clinical manifestations of the disease. Common and previous therapeutics strategies have not been beneficial for all patients, yet. So, there is increasing considerations, leading basic medical scientists toward new directions. During last decade, exponential growth of immune based methods with easy accessibility, less morbidity and operatively yields in clinical trials, has opened a new window to novel clinical applications. Recently, approaches with immunological perspectives such as special immunobiomarkers recruitment, stem cells and vectors have been appropriated to psoriasis immunotherapy purposes. Various evidences suggest that interleukin-35 (IL-35) has important roles in immune system regulation as a promising anti-inflammatory agent.  Also, it is demonstrated that Mesenchymal Stem Cells (MSCs) are able to hold anti-inflammatory and immunosuppressive properties, too. Here, we suggest a hypothetical cell and gene-based immunotherapy method that it could be advantageous for pro-inflammatory agents diminution in psoriatic patients. We hope that anti-inflammatory effects of IL-35 gene transfer via Adenoassociated virus as a vector by Bone Marrow derived-MSCs (BM-MSCs) in an Imiquimod-induced psoriasis-like mouse model, will probably be efficient in psoriasis global dilemma domination. Keywords: Psoriasis, IL-35, Mesenchymal stem cell, Regenerative medicine, Clinical applications.